Literature DB >> 20186482

Atorvastatin induces apoptosis in vitro and slows growth of tumor xenografts but not polyp formation in MIN mice.

Emina H Huang1, Laura A Johnson, Kathryn Eaton, Mark J Hynes, Joseph E Carpentino, Peter D R Higgins.   

Abstract

BACKGROUND: Despite the availability of effective surveillance for colorectal cancer with colonoscopy, relatively few at-risk individuals utilize this option. Colon cancer chemoprevention might be a more acceptable alternative. Some epidemiologic studies have suggested that statins may have chemopreventive effects without the risks of nonsteroidal anti-inflammatory drugs, but other epidemiologic studies have found no effect of statins.
METHODS: We aimed to evaluate the efficacy of atorvastatin in inducing apoptosis in vitro, in preventing polyp formation in the min mouse, and in preventing tumor growth in nude mice.
RESULTS: Atorvastatin rapidly induces apoptosis in the HCT116 colon cancer cell line in vitro, and this effect is reversible with mevalonate and geranylgeranyl pyrophosphate, but less so by farnesyl pyrophosphate. Atorvastatin chow was ineffective in reducing polyp formation in the min mouse model, with no significant effect on polyp number. Atorvastatin was effective in significantly slowing the growth of HCT116 colon cancer cell xenografts in nude mice (p = 0.008). Further, this reduction is due to increased levels of apoptosis.
CONCLUSIONS: Atorvastatin can induce apoptosis in vitro, through mevalonate and prenylation pathways. Atorvastatin, while not effective in preventing polyp formation in the min mouse model, was very effective in slowing tumor growth in a nude mouse model. Consistent with in vitro findings, increased apoptosis accounted for decreased tumor growth. Statins may have benefit in cancer by slowing tumor growth, rather than preventing tumor initiation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20186482      PMCID: PMC6557399          DOI: 10.1007/s10620-010-1157-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Prevalence of ras gene mutations in human colorectal cancers.

Authors:  J L Bos; E R Fearon; S R Hamilton; M Verlaan-de Vries; J H van Boom; A J van der Eb; B Vogelstein
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

2.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Authors:  S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

3.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.

Authors:  L Blais; A Desgagné; J LeLorier
Journal:  Arch Intern Med       Date:  2000 Aug 14-28

Review 4.  Drug insight: statins and gastrointestinal cancer.

Authors:  Taft P Bhuket; Peter D R Higgins
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2006-10

5.  Statins and the risk of colorectal cancer.

Authors:  Jenny N Poynter; Stephen B Gruber; Peter D R Higgins; Ronit Almog; Joseph D Bonner; Hedy S Rennert; Marcelo Low; Joel K Greenson; Gad Rennert
Journal:  N Engl J Med       Date:  2005-05-26       Impact factor: 91.245

6.  Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans.

Authors:  Vikas Khurana; Hanmanth R Bejjanki; Gloria Caldito; Michael W Owens
Journal:  Chest       Date:  2007-05       Impact factor: 9.410

7.  The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers.

Authors:  Liudmila L Kodach; Eliza Wiercinska; Noel F C C de Miranda; Sylvia A Bleuming; Alex R Musler; Maikel P Peppelenbosch; Evelien Dekker; Gijs R van den Brink; Carel J M van Noesel; Hans Morreau; Daniel W Hommes; Peter Ten Dijke; G Johan A Offerhaus; James C H Hardwick
Journal:  Gastroenterology       Date:  2008-03-04       Impact factor: 22.682

8.  Colorectal cancer screening adherence in a general population.

Authors:  Mark W Yeazel; Timothy R Church; Resa M Jones; Laura K Kochevar; Gavin D Watt; Jill E Cordes; Deborah Engelhard; Steven J Mongin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-04       Impact factor: 4.254

9.  The association between statins and cancer incidence in a veterans population.

Authors:  Wildon R Farwell; Richard E Scranton; Elizabeth V Lawler; Robert A Lew; Mary T Brophy; Louis D Fiore; J Michael Gaziano
Journal:  J Natl Cancer Inst       Date:  2008-01-08       Impact factor: 13.506

10.  Adherence to colorectal cancer screening guidelines in Canada.

Authors:  Maida J Sewitch; Caroline Fournier; Antonio Ciampi; Alina Dyachenko
Journal:  BMC Gastroenterol       Date:  2007-10-02       Impact factor: 3.067

View more
  9 in total

1.  Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin.

Authors:  Michael A Pereira; Blake M Warner; Thomas J Knobloch; Christopher M Weghorst; Ronald A Lubet; Vernon E Steele; Bruce C Casto
Journal:  Int J Cancer       Date:  2012-01-31       Impact factor: 7.396

2.  Simvastatin enhances radiation sensitivity of colorectal cancer cells.

Authors:  Georgios Karagkounis; Jennifer DeVecchio; Sylvain Ferrandon; Matthew F Kalady
Journal:  Surg Endosc       Date:  2017-09-15       Impact factor: 4.584

3.  Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.

Authors:  Yusuke Kobayashi; Hiroyasu Kashima; Ren-Chin Wu; Jin-Gyoung Jung; Jen-Chun Kuan; Jinghua Gu; Jianhua Xuan; Lori Sokoll; Kala Visvanathan; Ie-Ming Shih; Tian-Li Wang
Journal:  Clin Cancer Res       Date:  2015-06-24       Impact factor: 12.531

4.  Spironolactone and colitis: increased mortality in rodents and in humans.

Authors:  Laura A Johnson; Shail M Govani; Joel C Joyce; Akbar K Waljee; Brenda W Gillespie; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2011-11-13       Impact factor: 5.325

5.  Synergistic inhibition of colon cancer cell growth by a combination of atorvastatin and phloretin.

Authors:  Mo Zhou; Jinkai Zheng; Jinfeng Bi; Xinye Wu; Jian Lyu; Kun Gao
Journal:  Oncol Lett       Date:  2017-11-23       Impact factor: 2.967

6.  Anticancer activity of the cholesterol exporter ABCA1 gene.

Authors:  Bradley Smith; Hartmut Land
Journal:  Cell Rep       Date:  2012-09-13       Impact factor: 9.423

7.  Increased lanosterol turnover: a metabolic burden for daunorubicin-resistant leukemia cells.

Authors:  Claudia Stäubert; Rosanna Krakowsky; Hasanuzzaman Bhuiyan; Barbara Witek; Anna Lindahl; Oliver Broom; Anders Nordström
Journal:  Med Oncol       Date:  2015-12-23       Impact factor: 3.064

8.  Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta-analysis.

Authors:  Yue Li; Xingkang He; Yu'e Ding; Hongyang Chen; Leimin Sun
Journal:  Cancer Med       Date:  2019-05-08       Impact factor: 4.452

9.  High levels of triglycerides, apolipoprotein B, and the number of colorectal polyps are risk factors for colorectal polyp recurrence after endoscopic resection: a retrospective study.

Authors:  Jia-Yu Du; Gui-Ying Huang; Yong-Chun Xie; Nan-Xi Li; Zhi-Wei Lin; Li Zhang
Journal:  J Gastrointest Oncol       Date:  2022-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.